1 Emerging Challenges in Primary Care: 2017 Osteoporosis and Fracture Prevention Strategies
2 Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner Millennium Affiliated Physicians Division of Michigan Healthcare Professionals Farmington Hills, MI
3 Disclosures Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP serves as an advisory board committee member and speaker for Hologic (Self), Bayer (Spouse). Additionally, her spouse serves as a speaker for Smith and Nephew.
4 Learning Objectives 1. Discuss the diagnosis of osteoporosis and low bone mass Bone density testing FRAX 2. Discuss the role of non-pharmacologic agents in the prevention of bone fracture Calcium Vitamin D: treating deficiency and insufficiency Fall prevention
5 Learning Objectives 3. Discuss the pharmacologic treatment of low bone mass and osteoporosis 1. Bisphosphonate therapy including oral and infusion 2. SERMS 3. PTH 4. Rank Ligand Inhibitors 4. Discuss the current controversies in management of osteoporosis 1. Long term use of bisphosphonates 1. Osteonecrosis of the jaw (ONJ) 2. Atypical subtrochanteric fractures of the femur
6 Osteoporosis Overview
7 Osteoporosis: Definition A disease characterized by low bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk Pentice A Public Health Nutr 2004;7:227-43; WHO Study Group In Assessment of Facture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva: WHO, 1994 Photos courtesy of NAMS slide set for clinicians
8 A Gender Related Condition > Osteoporosis is the most common bone disorder affecting humans > The risk of hip fracture doubles for every 5- to 6- year increase in age from ages > Of the 10 million Americans estimated to have osteoporosis, 8 million are women (80%) Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
9 Vertebral Fractures Significant consequences for patients > Acute and chronic pain > Kyphosis and height loss > Impaired function > Increased morbidity and mortality > Increased fracture risk Delmas PD, et al. J Bone Miner Res. 2005;20:
10 Hip and Other Non-Vertebral Fractures Have Significant Consequences > Hip fracture associated with Loss of ambulatory status in 30% of patients Increased morbidity and mortality Increased fracture risk Major reason for admission to chronic care facilities > Non-vertebral fractures Pain Increased risk of future fractures Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
11 Fewer Than 35% of Hip Fracture Patients Receive Pharmacologic Treatment Within 6 Months Fracture Liason Service (FLS) > To identify and treat patients with a recent fragility fracture > Has been show to be effective and save money > Multidisciplinary system approach > Identifies patients at or proximate, to the time they are treated at the hospital for fracture > Provides easy access to osteoporosis care. Mitchell PJ. Best practices in secondary fracture prevention: fracture liaison services. Current Osteopor Reports. 2013;11:52 60
12 Risk Factors For Osteoporosis > Genetic factors > Environmental factors > Menstrual status > Disease states > Medications Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
13 Genetic Factors and Osteoporosis Risk > First-degree relative with osteoporosis or low-trauma fracture > Caucasian/Asian race > Slender physical frame Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
14 Disease States and Osteoporosis Risk > Primary hyperparathyroidism > Thyrotoxicosis > Cushing s syndrome > Rheumatoid arthritis > Malabsorption syndromes > Chronic liver/renal disease > Anorexia nervosa > Adult nontraumatic fracture Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
15 Medications and Osteoporosis Risk > Corticosteroids > Anticonvulsants > Anticoagulants > Immunosuppressive drugs > Levothyroxine > Lithium > Heparin Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
16 Fragility Fractures BONE ATTACK 1 Over age 40, when a trip or fall from a STANDING HEIGHT leads to FRACTURE > Defines a bone strength problem > Impacts future risk for subsequent fracture Bone Density is 70% Bone Quality is 30% > BMD for 40 and older > Need to consider therapy Risa Kagan MD, NAMS Fragility Fracture Video, 9/16
17 Synopsis of Major Recommendations to the Clinician for Bone Health: Apply to postmenopausal women and men age 50 and older > Counsel on the risk of osteoporosis and related fractures > Check for secondary causes > Advise on adequate amounts of calcium at least 1,200 mg per day > Advise on adequate amounts of Vitamin D 800-1,000 IU per day National Osteoporosis Foundation (NOF) Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
18 Synopsis of Major Recommendations to the Clinician: > Supplements if necessary for individuals age 50 and older > Recommend regular weight-bearing and musclestrengthening exercise to reduce the risk of falls and fractures > Advise avoidance of tobacco smoking and excessive alcohol intake Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2013
19 Who Should Have Bone Density Testing? Recommend Bone Mineral Testing (BMD) to: > Women age 65 and older > Men age 70 and older > Post-menopausal women and men age when there are concerns regarding risk profile > Those who have had a fracture, to determine degree of disease severity > BMD testing should be performed at DXA facilities using accepted quality assurance measures Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
20 NOF Treatment Guidelines 2014 After exclusion of secondary cause, treat postmenopausal women and men age 50 and older who have A fracture of the hip or vertebra (clinical or morphometric) T-score -2.5 or below in the femoral neck, total hip or spine T-score between -1.0 and -2.5 in the femoral neck or total hip or spine if 10-year risk to 3% for hip fracture or to 20% for major osteoporotic fractures based on FRAX model Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2013
21 Using FRAX To find those individuals at high risk for fracture, who are not yet osteoporotic! If your patient has osteoporosis by T-score, you do not have to look at FRAX. BUT, you may look at FRAX! More fractures occur in men and women with T-scores from -1.0 to -2.5!
22 FRAX: Gauging 10 Year Fracture Probability
24 Application of FRAX TM In the US > Intended for post-menopausal women and men age 50 and older > Has not been validated in patients currently or previously treated with pharmacotherapy for osteoporosis. In such patients, clinical judgment must be exercised in interpreting FRAX scores. Patients who have been off osteoporosis medication for 1 to 2 years or more might be considered untreated. Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014 Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2013
25 Application of FRAX TM In the US > Frax can be calculated with either femoral neck BMD or total hip BMD, but, when available, femoral neck BMD is preferred. Use of BMD from non hip sites is not recommended. > T scores must be converted to a reference standard to be used. The FRAX patch is available at to make the calculation > FRAX may be calculated by going to the FRAX calculator at the University of Sheffield website Clinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
26 Application of FRAX TM In the US The use of FRAX TM is for clinical guidance only and is not a rule. Consider intervention strategies for those: Who do not have osteoporosis by BMD Do not meet the cut points after FRAX Are not high enough risk of fracture despite low BMD Conversely, the recommendations do not mandate treatment Make decisions to treat on a case- by- case basis. atioclinicians Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation 2014
27 Obstacles in the Management of Osteoporosis > Insufficient rates of diagnosis > Low awareness by practitioners and patients of the imperative to treat > Global challenge to adherence to therapy in chronic disease > Uncertainly by practitioner and patients regarding treatment regimens and risk
28 Treatment When and How
29 NOF Guidelines: When to Treat Pharmacologic Treatment > Postmenopausal women or men over age 50 with a prior hip or spine fracture > Postmenopausal women or men over 50 with a BMD T- score of -2.5 or lower at the hip or spine > Postmenopausal women or men over 50 with T-score between -1 and -2.5 at the femoral neck, total hip, or spine if: 10 year probability (from FRAX) of hip fracture is 3% 10 year probability of a major osteoporosis-related fracture is 20% National Osteoporosis Foundation. Clinician s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis foundation; Washington, DC. 2014
30 Treatment Recommendations > No pharmacologic therapy should be considered indefinite in duration > After the initial three to five year treatment period, a comprehensive risk assessment should be performed > There is no uniform recommendation that applies to all patients and duration decisions need to be individualized National Osteoporosis Foundation. Clinician s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis foundation; Washington, DC. 2014
31 Non-Pharmacologic Interventions > Goal of non-pharmacologic intervention is to prevent future fractures through lifestyle change > The role of Vitamin D in osteoporosis May be important as both adjuvant and treatment Might be important in the response to therapy The effect on muscle strength, balance and risk of falls is important > Exercise > Fall Prevention
32 Current Pharmacologic Agents Approved for the Treatment of Osteoporosis > Anti-resorptive agents Bisphosphonates Weekly oral alendronate (Fosamax) Weekly or monthly risedronate (Actonel) Monthly oral or quarterly IV ibandronate (Boniva) Once yearly infusion Zoledronic Acid (Reclast) Rank Ligand Inhibitor Denosumab (Prolia) National Osteoporosis Foundation. Clinician s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis foundation; Washington, DC. 2014
33 Current Pharmacologic Agents Approved for the Treatment of Osteoporosis Calcitonin Selective estrogen receptor modulators (SERMS) Raloxifene (Evista) > Anabolic agents Parathyroid hormone - Teriparatide (Forteo) Abaloparatide (Tymlos)
36 Effects of Bisphosphonates > Decreased bone turnover > Increased BMD at spine and hip > Decreased risk of vertebral and hip fractures > Sustained effects with continued treatment > Best studied class of agents used in treating osteoporosis > Long term safety record Black DM, et al. Lancet. 1996;348: , Body J, et al. J Clin Endocrinol Metab. 2002;87:
37 ORAL BISPHOSPHONATES > Pros Osteoporosis prevention and treatment Reduction in risk of vertebral fractures (w/ and w/o pre-existing fx) > Cons Require lifestyle change empty stomach water only may lead to noncompliance GI adverse effects Marginal efficacy in nonvertebral fractures (e.g. hip) Long-term safety is unconfirmed
38 Absorption and Tolerability of Oral Bisphosphonates Are Affected When Dosing Instructions are not Followed > Coffee or juice can reduce absorption by as much as 60% > Calcium supplements can interfere with absorption and should not be taken at the same time as oral bisphosphonate therapy > GI side effects are more likely when dosing instructions are not followed > Even when complete instructions are given, between 25% and 50% of patients disregard at least one requirement Gert FJ, et al. Clin Pharmacol Ther. 1995;58d: d, Seeman E, et al. Osteoporos Int. 2007;a8:
39 IV Bisphosphonate
40 Zoledronic Acid
41 Zoledronic Acid HORIZON Fracture Trials: Efficacy Conclusions > Reduces incidence of vertebral fractures by 70% (with significant reduction at 1 year) > Reduces hip fractures by 41% > Reduces nonvertebral fractures by 25%, over 3 years in patients with osteoporosis, defined by prevalent vertebral fractures and osteoporosis by BMD of the hip Black DM, etal. N Engl J Med. 2007;356:
42 Bioavailability and High Binding Affinity Allow Zoledronic Acid to be Dosed Once Yearly > Zoledronic acid bypasses the GI tract, eliminating absorption limitations > Year long efficacy of zoledronic acid is attributable to the high binding affinity of zoledronic acid to bone > Bioavailability: approximately 61% directly to bone Approximately 39% eliminated from circulation within 24 hours Zoledronic acid (prescribing information) East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2008
43 Rank Ligand Inhibitor Denosumab
44 Denosumab RANK Ligand Inhibitor > Fully human monoclonal antibody > Specifically targets a ligand called RANKL (that binds to a receptor called RANK) which is a key mediator of: Osteoclast formation Function Survival > Improves cortical and trabecular bone density, volume and strength > Currently being studied across a range of conditions including osteoporosis, treatment induced bone loss, bone metastases, multiple myeloma and rheumatoid arthritis
45 Denosumab Significantly Reduced Fracture Risk at Key Sites* Phase 3 Trial *Key sites: vertebral, hip, and nonvertebral; includes 7393 pa>ents with a baseline and at least one post- baseline radiograph; composite measurement excluding pathological fractures and those associated with severe trauma, fractures of the vertebrae, skull, face, mandible, metacarpals, fingers, and toes. > Vertebral: 68% RRR p< > Hip: 40% RRR p=0.04 > Non- vertebral: 20% RRR p=0.01 *Key sites: vertebral, hip, and nonvertebral; includes 7393 pa>ents with a baseline and at least one post- baseline radiograph; composite measurement excluding pathological fractures and those associated with severe trauma, fractures of the vertebrae, skull, face, mandible, metacarpals, fingers, and toes. Denosumab prescribing informa>on, Amgen. Cummings SR, et al. N Engl J Med. 2009;361:
46 New Agent: Romosozumab Not yet FDA approved: > Monoclonal antibody that binds sclerostin Increases bone formation Decreases bone resorption Rapid onset of fracture reduction, in the first 6 months > Adverse events were balanced in the 12 and 24 month studies between placebo and treatment groups > One atypical fracture and 2 cases of osteonecrosis of the jaw in the treatment group Felicia Cosman, M.D., Daria B. Crittenden, M.D., Jonathan D. Adachi, M.D., et al, Romosozumab Treatment in Postmenopausal Women with Osteoporosis, N Engl J Med 2016; 375:
47 Osteoporosis Treatment Anabolic Agents: PTH
48 Effects of Parathyroid Hormone > Stimulates osteoblast activity preferentially > Increases bone turnover and creates a positive bone balance > Improves trabecular microarchitecture and increases cortical thickness > Increases bone mass > Decreases risk of vertebral and nonvertebral fractures > Requires daily injections Neer RM, et al. N Engl J Med. 2001:344: ,
49 Mode and Amount of Parathyroid Hormone Determines its Predominant Bone Activity MODE EFFECT Continuous Catabolic (high dose) Intermittent Anabolic (low dose)
50 Parathyroid Hormone > Pros Osteoporosis treatment Reduction in risk of vertebral and nonvertebral fractures May be used in conjunction with other OP therapies (e.g. antiresorptive) > Cons Osteosarcoma risk? Long-term use not established Long-term safety not established Hip fracture prevention? Daily sq injections Nausea, headache, etc.
51 Teraparatide > FDA approved 2002 > Recombinant human parathyroid hormone analog (1-34), [rhpth(1-34)] indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture > Self administered subcutaneous infection for 2 years followed by bisphosphonate therapy > Carries a label warning regarding osteosarcoma
52 Abaloparatide FDA approved 4/28/17 > Indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture defined as: A history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy > Lab-made copy of part of the human parathyroid hormonerelated protein (PTHrP) > Daily subcutaneous injection > Recommended for two years and followed with bisphosphonates for several years > Carries a label warning regarding osteosarcoma > Side effects include nausea, dizziness, and vomiting
54 Effects of SERMS (Estrogen agonist/antagonists) > SERMS exert estrogen like effects on the skeleton > Decrease bone turnover > Increase bone density, but to a lesser degree than with bisphosphonates > Decrease risk of vertebral fracture > No hip or non-vertebral fracture Ettinger B, et al.,jama.1999; 282:637-85
55 Raloxifene > Pros Osteoporosis prevention No endometrial or breast stimulation LDL reduction > Cons No current nonvertebral fracture data (e.g. hip) No effect on vasomotor symptoms Thrombosis Effects on cholesterol are modest Leg cramps Fuleihan. N Engl J Med. 1997;337: Editorial.
56 Hormone Therapy Estrogen Therapy Approved for prevention only
57 Hormone Replacement Therapy (HRT, Estrogen) > Pros Osteoporosis prevention Cognitive benefits (?) Urogenital symptom improvement > Cons Withdrawal bleeding Endometrial cancer with unopposed estrogen Breast cancer Heart attack Stroke Thrombosis
58 Addressing Recent Controversies in the Treatment of Osteoporosis
59 Addressing Recent Controversies > Treatment decisions require risk and benefit discussions > What was acceptable risk previously, may no longer be acceptable > If disease state risk is high: fracture Risk of rare complications may be outweighed
60 Addressing Recent Controversies > Long term use of bisphosphonate therapy > Bisphosphonate therapy and the occurrence of fractures of the subtrochanteric or diaphyseal femur > Osteonecrosis of the jaw (ONJ)
61 Length of Use of Bisphosphonates FDA review in the New England Journal of Medicine, May 31, 2012 > Some patients may be able to stop using after 3 to 5 years and still receive benefit of the drug > Long term risk: still unknown Optimal period of use to maximize effectiveness and decrease risk Is it beneficial to stop drug and start taking again?
62 Long Term Use of Bisphosphonates New Guidance: The American Society for Bone and Mineral Research (ASBMR) > Result of 2 clinical trials found that long-term treatment with the medications reduced the likelihood of fractures in women at high risk > Women should be reassessed for risk after 5 years of oral treatment and after 3 years of IV treatment > Women at high risk for fractures should continue oral treatment for up to 10 years and IV for up to 6 years with intermittent follow-up > Women whose risk of fractures decreases after 3 to 5 years should stop treatment for 2 to 3 years Adler RA, EL-Hajj, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1): 19-35
63 Long Term Use of Bisphosphonates > The suggested approach for long term use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment Adler RA, EL-Hajj, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1): 19-35
64 Use of Drug Holidays in Women Taking Bisphosphonates NAMS Practice Pearl > Bisphosphonates are the cornerstone of treatment for osteoporosis > Generally safe and well-tolerated > For most patients at moderate or high risk: benefits of treatment far outweigh the serious, but RARE risks > Bisphosphonates accumulate in bone with some persistent protective effect after therapy is stopped > This makes it reasonable to consider a drug holiday from bisphosphonate therapy
65 Use of Drug Holidays in Women Taking Bisphosphonates > The duration and length of the holiday should be based on clinical judgment Individualize based on risk/benefit assessments Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates, NAMS Practice Bulletin, Released April 1, 2013.
66 Low Risk of Fracture Bisphosphonate therapy should be discontinued if it has been prescribed Example: 52 yo old woman, menopause at age 50, lowest T-score -1.4, no risk factors, bisphosphonate therapy for 2 years Treatment was not indicated in the first place. Discontinue Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates, NAMS Practice Bulletin, Released April 1, 2013.
67 Mild Risk of Fracture Treat with bisphosphonate for 3-5 years, then offer a drug holiday Example: 68 yo woman, menopause age age 48, lowest T-score -2.3, parent with a hip fracture, bisphosphonate therapy for 5 years and BMD stable over that time Treatment was indicated, but a drug holiday might be considered after 5 years of treatment Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates, NAMS Practice Bulletin, Released April 1, 2013.
68 Moderate Risk of Fracture > Treat with a bisphosphonate for 5 to 10 years, then offer drug holiday of 3-5 years, no risk factors, bisphosphonate therapy for 8 years and BMD increased over that time with a current lowest T- score > Treatment was indicated but after 8 years of treatment, a drug holiday might be considered. Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates, NAMS Practice Bulletin, Released April 1, 2013.
69 High Risk of Fracture > Treat with bisphosphonate for 10 years, then offer a drug holiday of 1-2 years. A non-bisphosphonate. > Example: 70 year old woman, menopause at age 45, lowest initial T-score -3.5 > Requiring ongoing corticosteroid therapy for rheumatoid arthritis, history of a vertebral fracture, bisphosphonate therapy for 10 years. > Treatment was indicated and she remains at high risk of fracture after 10 years. If a holiday from the bisphosphonate is considered, interval treatment with teriparatide or raloxifene would be prudent Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates, NAMS Practice Bulletin, Released April 1, 2013.
70 Fractures of the Subtrochanteric or Diaphyseal Femur FDA Safety Communication - 3/10/2010 > Reports out of the American Academy of Orthopedic Surgeons: Is an increased risk of a rare femur fracture in patients with osteoporosis using bisphosphonates? > At this point, the data that FDA has reviewed: Have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures. > FDA is working closely with outside experts: Recently convened American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force to gather additional information that may provide more insight into this issue.
71 Fractures of the Subtrochanteric or Diaphyseal Femur National Osteoporosis Foundation (NOF) Position Statement for Patients > Based on information that is currently available, NOF believes that for most people taking bisphosphonate medicines, the benefits outweigh the risks of these unusual, but serious conditions that appear to be associated with them.
72 Osteonecrosis of the Jaw (ONJ) > Jaw lesions, usually after dental extraction have been observed with bisphosphonate use Most often in patients treated with large IV doses for cancer-related bone diseases. 1,2 > ONJ has been defined as a delay in healing of an oral lesion after surgery or extraction for more than 6 to 8 weeks. 1.Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62: Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:
73 Osteonecrosis of the Jaw (ONJ) > Cases have also been reported in patients receiving bisphosphonate therapy for osteoporosis. > The incidence of these lesions is not known and a causal association between bisphosphonates and osteonecrosis has not been documented. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society, Menopause, Vol. 17, No. 1, 2010
74 Osteonecrosis of the Jaw (ONJ) > There are no data to recommend the discontinuation of bisphosphonate therapy before dental extraction (although therapy may be suspended until the oral lesion has healed). > There are no data to suggest that dental surgery is contraindicated in patients on bisphosphonate therapy. > Routine dental care is recommended for all patients. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society, Menopause, Vol. 17, No. 1, 2010
75 Summary > Osteoporosis is under diagnosed and preventative care is under utilized > Current practice requires dialogue between patient and practitioner in regards to individual risk and risk and benefits of therapeutic options > Treatment strategies must be individualized to obtain greater compliance to therapy > Practitioners will need to stay current while treatment recommendations continue to be reviewed and possibly changed
76 Cases BMD FRAX The Art of Managing Osteoporosis and Fracture Prevention!
77 Case #1 > 72 year old Caucasian woman > Non-smoker > F.H. Osteoporosis in Mother > Negative for secondary causes of osteoporosis
81 Case #2 > 52 year old Caucasian > Non-smoker > Negative for secondary causes of Osteoporosis
85 Case #3 > 63 yo woman has a family history of breast cancer in her Mother. > Bone density test LS: T-score -2.4 Hip: -1.6 at femoral neck > Does she have osteoporosis? > Is it important to look at her FRAX score? > What are her options for therapy?
86 Case #3 > Pt prefers to take Raloxifene and starts the medication > What risk factors are important to identify for this patient? > The patient has her bone density repeated in 2 years and stays on her Raloxifene > 2 years later her BMD shows a T score of -2.5 in the femoral neck > What will you do about her treatment plan? > Will she stay on Raloxifene?
87 Case # 4 82 yo woman LS: normal with -0.9 Hip: Moderate low bone mass (Osteopenia) -2.0 Patient has never been treated with pharmacologic therapy. She denies problem with swallowing, GERD or known esophagus problem. She has mild CKD and is being followed by a nephrologist.
89 Would you treat this patient? What would you prescribe?
90 Case #5 85 yo woman BMD shows: LS: Mild low bone mass with T score of -1.4 Hip: Osteoporosis with T score of -2.8 Patient has been on oral bisphosphonate therapy for 8 years and is not having any problem.
92 Long Term Use of Oral Bisphosphonate > Would you continue her therapy? > Is she at high risk for fracture? > Would her FRAX calculation make any difference in your treatment decision? > Is the FRAX calculation always correct when based on the patient answers to the questionnaire?
93 What does her FRAX calculation look like? Was the demographic data entered correctly?
94 FRAX is only as accurate as the information that is entered. Recalculation can be done if there is any question.
95 Case #6 84 yo woman > On alendronate: length of time unknown > History of right hip fracture > LS T-score -1.8 > Hip -3.0
98 Case #6 > Will you keep this patient on Alendronate? > Is she taking the medication correctly and consistently? > What is her fall risk? > What is her preference? > Is she an active 84 yo old? > Will her insurance cover once a year infusion, twice a year injection or daily PTH?
99 Case #7 84 yo on long term oral bisphosphonate therapy for over 10 years. BMD: LS: Severe osteoporosis T score -4.6 Hip: Severe osteoporosis T score -3.7 I referred the patient to the endocrinologist for an opinion.
101 Have you ever seen a FRAX this high?? What are the options for treating this patient?
102 Case # 7 > What would you recommend for this patient who has been on long term bisphosphonate therapy? > She is at very high risk for fracture!! > What are your options? > What did the endocrinologist recommend?
103 Bibliography > Adler RA, EL-Hajj, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):19-35 > Felicia Cosman, M.D., Daria B. Crittenden, M.D., Jonathan D. Adachi, M.D., et al, Romosozumab Treatment in Postmenopausal Women with Osteoporosis, N Engl J Med 2016; 375: > Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates, NAMS Practice Bulletin, Released April 1, > International Society for Clinical Densiometry. (2012). Osteoporosis screening guidelines. Retrieved from osteoporosis-screening-guidelines > National Osteoporosis Foundation. (2013). Clinician s guide to prevention and treatment of osteoporosis. Washington, DC: Author. Retrieved from
104 Bibliography > Nelson, H. D., Haney, E. M., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010). Screening for osteoporosis: Systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 77. AHRQ Publication No EF-1. Rockville, MD: Agency for Healthcare Research and Quality. > Miller P, Hattersley G, Riis B J Effect of Abaloparatide vs Placebo in New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial JAMA 2016;316(7): doi: /jama > North American Menopause Society. (2010a). Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause, 17(1), doi: /gme. 0b013e3181c617e6 > North American Menopause Society. (2010b). Disease risk in menopause practice: A clinician s guide (4th ed.). Mayfield Heights, OH: Author.
105 Bibliography > Qaseem A, Forciea MA, McLean RM, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. Ann Intern Med. [Epub ahead of print 9 May 2017] doi: /M > Siris, E., & Delmas, P. D. (2008). Assessment of 10-year absolute fracture risk: A new paradigm with worldwide application. Osteoporosis International, (19)4, doi: /s > Szulc, P., & Delmas, P. D. (2008). Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis. Osteoporosis International, 19(12), doi: / s > Tymlos [package insert]. St. Waltham, MA: Radius Health; > Wagner, E. H., Williams, C. A., Greenberg, R., Kleinbaum, D., Wolf, S. H., & Ibrahim, M. A. (2009). Simply ask them about their balance Future fracture risk in a national cohort study of twins. American Journal of Epidemiology, 169, 143. doi: /aje/kwn379 > World Health Organization Collaborating Center for Metabolic Bone Diseases. (n.d.). FRAX tool, online. Retrieved from
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION Debra L. Sietsema, PhD, RN Director, Bone Health Clinical Operations October 5, 2016 OTA NP/PA Course 1 Osteoporosis Definition A skeletal disorder characterized
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330702 Managing Osteoporosis: Screening, Treatment, and More Osteoporosis is
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
Osteoporosis Steven W. Ing, M.D., MSCE Assistant Professor of Internal Medicine Department of Internal Medicine Division of Endocrinology, Diabetes, & Metabolism Ohio State University Medical Center Case
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
Kristie N. Tu, PharmD, BCPS, CGP; Janette D. Lie, PharmD, BCACP; Chew King Victoria Wan, PharmD Candidate; Madison Cameron, PharmD Candidate; Alaina G. Austel, PharmD Candidate; Jenny K. Nguyen, PharmD
Osteoporosis Diagnosis, Treatment and Controversies Feb, 2018 Shawn Baca, M.D., F.A.C.R. Rheumatology Associates of South Florida RASF RASF Clinical Research Osteoporosis Diagnosis and Treatment Center
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
Sandra Scholten, FNP-BC Discuss burden of osteoporosis (OP) and clinical consequences of OP fractures. Define OP and techniques used to assess bone density and quality. Improve awareness, diagnosis, and
Management of Osteoporosis Clinical Practice Guideline September 2013 MedStar Health and MedStar Family Choice accept and endorse the clinical guidelines set forth by the National Osteoporosis Foundation
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now? Steven M. Petak, MD, JD, FACE, FCLM Texas Institute for Reproductive Medicine And Endocrinology, Houston, Texas
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
in Health and Disease James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation 52 y.o. woman presented in April
Osteoporosis Introduction Osteoporosis is a very common bone disease that causes bone to become weak. Bone weakness can lead to fractures of the spine, hip, and wrist from simple falls or even a sneeze
Awareness, Diagnosis, and Management of Osteoporosis in Adults with Developmental Disabilities Sunil J. Wimalawansa, MD, PhD, MBA, FACP, FRCP University Professor Professor of Medicine, Physiology & Pharmacology
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
Atypical Femoral Fractures Insights and Enigmas Madhu Mehta, M.D. Clinical Asst. Prof. of Medicine Department of Immunology/Rheumatology The Ohio State University Abreviations used TFF- Typical femoral
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Who gets Osteoporosis Bone Tested and Why Steve Kane, MD Chairman, AMC Orthopedic Surgery Residency Topics for which I should never be at the podium How I summited Mt. Everest How I found the Titanic My
Osteoporosis A Silent Killer David A. Chappell, MD Endocrinology Private Practice Petaluma, California Relevant Disclosures Speakers Bureau Astra Zeneca Boehringer Ingelheim AACE/ACE Guidelines American
Osteoporosis Evaluation and Treatment Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism October 28, 2011 No conflicts of interest Objectives Explain when to initiate
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
Clinical Practice Guideline Adult Osteoporosis Version 1.1.2016 June 2016 Unpublished work (c) 2016 United Rheumatology, LLC Table of Contents Introduction... 5 Establishing the Diagnosis of Osteoporosis
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
Bisphosphonate Treatment for steoporosis: Do the Benefits utweigh the Risks? 37 th Annual Advances in Internal Medicine May 18 and June 22, 29 hsponsored resentations Disclosures Eli Lilly & Company, GlaxoSmithKline,
What Is FRAX & How Can I Use It? Jacqueline Osborne PT, DPT Board Certified Geriatric Clinical Specialist Certified Exercise Expert for the Aging Adult Brooks Rehabilitation; Jacksonville, FL Florida Physical
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
Bone Health in Women: Getting Strong and Staying Strong Family Medicine Refresher Course Jeannette E. South-Paul, M.D. Andrew W. Mathieson UPMC Professor and Chair University of Pittsburgh Department of
Osteoporosis Update: Review of Current Guidelines, Controversies, and Common Questions Holly Hofkamp, MD OHSU Family Medicine, Assistant Professor 4/25/14 No disclosures Goals/Objectives Highlight current
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru223 Topic: Prolia, denosumab Date of Origin: August 11, 2010 Committee Approval Date: August 11,
FRAX, NICE and NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Research funding and/or honoraria and/or advisory boards for: o ActiveSignal, Amgen, Bayer, Boehringer
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
Osteoporosis Products Available in Canada for the Treatment and Prevention of Postmenopausal Osteoporosis Physician Desk Reference - 2nd Edition A clinical resource provided to you by: The Society of Obstetricians
Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value Final Evidence Report July 17, 2017 Prepared for Note: When our process began, ICER expected FDA approval of two new
Osteoporosis Update Diagnosis and Management Kara Hawkins, MD Sentara Martha Jefferson Hospital Charlottesville, VA No disclosures Learning Objectives Know when to suspect secondary causes of osteoporosis
216 Clinical Pharmacist May 2009 Vol 1 Several guidelines exist for the identification and treatment of osteoporosis. Patients diagnosed with the condition should be prescribed bisphosphonates, if suitable,
Management of Osteoporosis Clinical Practice Guideline These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care of their patients. They are not a substitute
The Future of Ost eoporosis Care in Research and Practice ACOI Luncheon October 26, 2010 Steven T Harris MD FACP Clinical i l Profess sor of fmedicine i University of California, San Francisco Treatment
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
Diagnosis and management of osteoporosis Ralston SH, Fraser J. Diagnosis and management of osteoporosis. Practitioner 2015;259 (1788):15-19 Professor Stuart H Ralston MD FRCP Professor of Rheumatology,
Conflict of Interest -primary prevention and secondary fracture prevention for the Advanced Practice Nurse Anne Lake, DNP, ONP-C, FNP-C, CCD I hereby certify that, to the best of my knowledge, no aspect
International Journal of Advanced Research and Review www.ijarr.in EFFECT OF INTRAVENOUS ZOLENDRONIC ACID ON BONE MINERAL DENSITY IN POST MENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY OF NORTH WEST PART
5 Quality Department Guidelines for Clinical Care Ambulatory Osteoporosis Guideline Team Team Lead Robert W. Lash, MD Endocrinology Team Members R. Van Harrison, PhD Medical Education Jane T. McCort, MD
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee